VEGF-C Antibody [Biotin]

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

VEGF-C Antibody [Biotin] Summary

• Immunogen: recombinant human VEGF-C
• Specificity: Detects human VEGF-C in Western blots. In this format, less than 1% cross‑reactivity is observed with rhVEGF₁₂₁ and rhVEGF_165b.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: VEGFC
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.1 ug/mL
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VEGF-C Antibody [Biotin]

• Flt4 ligand
• Flt4-L
• vascular endothelial growth factor C
• Vascular endothelial growth factor-related protein
• VEGFC
• VEGF-C
• VRPFLT4 ligand DHM

Background

Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a VEGF sub-family that share the conserved VEGF homology domain (VHD) with other VEGF family members but are distinguished by their preferential formation of non-covalent homodimers. Both VEGF-C and -D have long N- and C-terminal propeptide extensions. The VEGF-C propeptide undergoes stepwise proteolytic processing to generate ligands with increasing affinity for VEGF-R3. However, only the fully processed VEGF-C containing just the VHD can bind VEGF-R2. None of the VEGF-C forms have appreciable affinity for VEGF-R1. VEGF-C is expressed in multiple adult human tissues, most prominently in lymph nodes, heart, placenta, ovary, and small intestine. Traces of VEGF-C are also detected in brain, liver, thymus, skeletal muscles, spleen, prostate, testis and colon. Unlike other VEGF family members, VEGF-C expression is not regulated by hypoxia. VEGF-C is a lymphangiogenic growth factor and the VEGF-C/VEGF-R3 signaling pathway has been shown to be crucial for lymphangiogenesis. VEGF-C and VEGF-R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. VEGF-C stimulates lymphangiogenesis in the avian chorioallantoic membrane model. Over-expression of VEGF-C in breast cancer cells has been shown to increase intratumoral lymphangiogenesis, resulting in enhanced metastasis to regional lymph nodes and to the lungs. Mouse tumors expressing elevated levels of VEGF-C have increased lymphatic metastasis and increased lymphatic surface area in the tumor margin. VEGF-C is also associated with lymph node metastasis of colorectal carcinoma. Besides lymphangiogenesis, VEGF-C can have potent effects on physiological angiogenesis through its interaction with VEGF R2. The protein can stimulate migration and proliferation of endothelial cells in vitro and in vivo and has been shown to stimulate angiogenesis in the mouse cornea and in rabbit hind limb ischaemia (1 - 10).

1. Joukov, V. et al. (1996) EMBO J. 15:290.
2. Joukov, V. et al. (1997) EMBO J. 16:3898.
3. Lee, J. et al. (1996) Proc. Natl. Acad. Sci. USA 93:1988.
4. Oh, S. et al. (1997) Dev. Biol. 188:96.
5. Witzenbichler, B. et al. (1998) Am. J. Pathol. 153:381.
6. Cao, Y. et al. (1998) Proc. Natl. Acad. Sci. 95:14389.
7. Stacker, S and M. Achen (1999) Growth Factors 17:1.
8. Akagi, K. et al. (2000) Br. J. Cancer 83:887.
9. Skobe, M. et al. (2001) Nature Medicine 2:192.
10. Padera, T.P. et al. (2002) Science 296:1883.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGF-C Antibody (BAF752)(3)

Publications using BAF752

• Cassuto, J;Folestad, A;Göthlin, J;Malchau, H;Kärrholm, J; VEGF-A, -C, -D, VEGFR1, -2, -3, PDGF-BB and FGF-2 join forces to induce vascular and lymphatic angiogenesis during bone healing of hip implants Bone reports 2025-09-01 [PMID: 40688801] (ELISA Detection, Human)
• Le Guen L, Karpanen T, Schulte D, Harris N, Koltowska K, Roukens G, Bower N, van Impel A, Stacker S, Achen M, Schulte-Merker S, Hogan B Ccbe1 regulates Vegfc-mediated induction of Vegfr3 signaling during embryonic lymphangiogenesis. Development, 2014-02-12;141(6):1239-49. 2014-02-12 [PMID: 24523457] (Western Blot, Human)
• Goldman J, Conley KA, Raehl A, Bondy DM, Pytowski B, Swartz MA, Rutkowski JM, Jaroch DB, Ongstad EL Regulation of lymphatic capillary regeneration by interstitial flow in skin. Am. J. Physiol. Heart Circ. Physiol., 2006-12-22;292(5):H2176-83. 2006-12-22 [PMID: 17189348] (IHC-Fr, Mouse)

FAQs for VEGF-C Antibody (BAF752). (Showing 1 - 1 of 1 FAQs).

1. I was wondering if you know of any blocking antibodies against IL-6 or VEGF-C that can be used in cell culture to quench these cytokines?
   • We have no antibodies that are currently known to show blocking antibodies to VEGF-C. Please see this link to our IL-6 antibodies with blocking/neutralizing activity can be found at this link.

Bioinformatics

• Gene Symbol: VEGFC